Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73583800" target="_blank" >RIV/61989592:15110/17:73583800 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.degruyter.com/downloadpdf/j/cclm.2017.55.issue-12/cclm-2017-0797/cclm-2017-0797.pdf" target="_blank" >https://www.degruyter.com/downloadpdf/j/cclm.2017.55.issue-12/cclm-2017-0797/cclm-2017-0797.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/cclm-2017-0797" target="_blank" >10.1515/cclm-2017-0797</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

Popis výsledku v původním jazyce

In the current multidisciplinary management of cancer patients, the role of laboratory medicine is as indispensable as the role of surgical, medical or radiation oncology [1]. Much of the progress that we have witnessed during the last decades in the therapy of cancer patients is associated with the advent of targeted treatment. Apart from an anatomical targeting [2], the targeted therapy is critically dependent on the identification of a therapeutic target, i.e. a pathogenic mechanism or pathway distinguishing neoplastic from normal tissue that correspond to the hallmarks of cancer defined by Hanahan and Weinberg [3]. Biomarkers reflecting these hallmarks of cancer are of critical importance in guiding the targeted therapy.

Název v anglickém jazyce

Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers)

Popis výsledku anglicky

In the current multidisciplinary management of cancer patients, the role of laboratory medicine is as indispensable as the role of surgical, medical or radiation oncology [1]. Much of the progress that we have witnessed during the last decades in the therapy of cancer patients is associated with the advent of targeted treatment. Apart from an anatomical targeting [2], the targeted therapy is critically dependent on the identification of a therapeutic target, i.e. a pathogenic mechanism or pathway distinguishing neoplastic from normal tissue that correspond to the hallmarks of cancer defined by Hanahan and Weinberg [3]. Biomarkers reflecting these hallmarks of cancer are of critical importance in guiding the targeted therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Chemistry and Laboratory Medicine

ISSN

1434-6621

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

4

Strana od-do

1813-1816

Kód UT WoS článku

000414045500009

EID výsledku v databázi Scopus

—